DHW-221

N/A

Report date: 2022/03/29 14:00:42
NME

Base Information

Drug NameDHW-221
Drug Alias NameDHW-221
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase mTOR inhibitorsPhosphatidylinositol 3 kinase beta inhibitors
TargetsSerine/threonine-protein kinase mTORPhosphatidylinositol 3 kinase beta
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShenyang Pharmaceutical University
China Registration ClassN/A

Develop Information

Active CompaniesShenyang Pharmaceutical University
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A